Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: Avoiding crystal growth using excipients

International Journal of Pharmaceutics

Volumn 454, Issue 2, 2013, Pages 668-677

  Pham, Dinh Duy ^a,b   Fattal, Elias ^a   Ghermani, NourEddine ^a,c   Guiblin, Nicolas ^c   Tsapis, Nicolas ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^c LABORATOIRE STRUCTURES   (France)

Author keywords

Crystallization; Large porous particle; Lung delivery; Pyrazinamide; Tuberculosis

Indexed keywords

ALCOHOL; AMMONIA; BICARBONATE; DIPALMITOYLPHOSPHATIDYLCHOLINE; EXCIPIENT; HYALURONIC ACID; LEUCINE; PYRAZINAMIDE; WATER;

ARTICLE; CRYSTALLIZATION; DENSITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; PARTICLE SIZE; PRIORITY JOURNAL; SPRAY DRYING;

CRYSTALLIZATION; LARGE POROUS PARTICLE; LUNG DELIVERY; PYRAZINAMIDE; TUBERCULOSIS;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADMINISTRATION, INHALATION; ANTITUBERCULAR AGENTS; BICARBONATES; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; EXCIPIENTS; HYALURONIC ACID; LEUCINE; PARTICLE SIZE; POROSITY; POWDER DIFFRACTION; PYRAZINAMIDE; X-RAY DIFFRACTION;

EID: 84884168091     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.016     Document Type: Article

References (49)

1. Borba, A., Albrecht, M., Gomez-Zavaglia, A., Suhm, M.A., Fausto, R., 2010. Low temperature infrared spectroscopy study of pyrazinamide: from the isolated monomer to the stable low temperature crystalline phase. J. Phys. Chem. A 114, 151-161.
2. Castro, R.A.E., Maria, T.M.R., Evora, A.O.L., Feiteira, J.C., Silva, M.R., Beja, A.M., Canotilho, J., Eusebio, M.E.S., 2010. A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships. Cryst. Growth Des. 10, 274-282.
3. Cherukuvada, S., Thakuria, R., Nangia, A., 2010. Pyrazinamide polymorphs: relative stability and vibrational spectroscopy. Cryst. Growth Des. 10, 3931-3941.
4. Chiş, V., Pirnǎu, A., Jurča, T., Vasilescu, M., Simon, S., Cozar, O., David, L., 2005. Experimental and DFT study of pyrazinamide. Chem. Phys. 316, 153-163.
5. Cruz, L., Fattal, E., Tasso, L., Freitas, G.C., Carregaro, A.B., Guterres, S.S., Pohlmann, A.R., Tsapis, N., 2011. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J. Controlled Release 152, 370-375.
6. Ducati, R.G., Ruffino-Netto, A., Basso, L.A., Santos, D.S., 2006. The resumption of consumption: a review on tuberculosis. Memórias do Instituto Oswaldo Cruz 101, 697-714.
7. Dunbar, C.A., Hickey, A.J., Holzner, P., 1998. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona 16, 7-45.
8. Edwards, D.A., 2002. Delivery of biological agents by aerosols. AIChE J. 48, 2-6. (Pubitemid 36858922)
9. Edwards, D.A., Dunbar, C., 2002. Bioengineering of therapeutic aerosols. Annu. Rev. Biomed. Eng. 4, 93-107. (Pubitemid 35217416)
10. Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., Mintzes, J., Deaver, D., Lotan, N., Langer, R., 1997. Large porous particles for pulmonary drug delivery. Science 276, 1868-1871. (Pubitemid 27443665)
11. Esteves de Castro, R.A., Canotilho, J., Barbosa, R.M., Silva, M.R., Beja, A.M., Paixão, J.A., Redinha, J.S., 2007. Conformational isomorphism of organic crystals: racemic and homochiral atenolol. Cryst. Growth Des. 7, 496-500.
12. Gervelas, C., Serandour, A.L., Geiger, S., Grillon, G., Fritsch, P., Taulelle, C., Le Gall, B., Benech, H., Deverre, J.R., Fattal, E., Tsapis, N., 2007. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. J. Controlled Release 118, 78-86. (Pubitemid 46283100)
13. Gómez Gaete, C., Tsapis, N., Silva, L., Bourgaux, C., Fattal, E., 2008. Morphology, structure and supramolecular organization of hybrid 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine-hyaluronic acid microparticles prepared by spray drying. Eur. J. Pharm. Sci. 34, 12-21.
14. Grodon, J.D., 1995. Antituberculous therapy. In: Lutwick, L.I. (Ed.), Tuberculosis. A Clinical Handbook. Chapman & Hall, New York, pp. 295-316.
15. Heifets, L., Lindholm-Levy, P., 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. J. Respir. Crit. Care Med. 145, 1223-1225.
16. Hu, Y., Coates, A.R., Mitchison, D.A., 2006. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 10, 317-322.
17. Kawaguchi, H., Koiwai, N., Ohtsuka, Y., Miyamoto, M., Sasakawa, S., 1986. Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles. Biomaterials 7, 61-66. (Pubitemid 16151617)
18. Kim, S.J., Hahn, S.K., Kim, M.J., Kim, D.H., Lee, Y.P., 2005. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Controlled Release 104, 323-335.
19. Krenis, L.J., Strauss, B., 1961. Effect of size and concentration of latex particles on respiration of human blood leucocytes. Proc. Soc. Exp. Biol. Med. 107, 748-750.
20. Lechuga-Ballesteros, D., Charan, C., Stults, C.L.M., Stevenson, C.L., Miller, D.P., Vehring, R., Tep, V., Kuo, M.-C., 2008. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J. Pharm. Sci. 97, 287-302.
21. Lucas, P., Anderson, K., Potter, U.J., Staniforth, J.N., 1999. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm. Res. 16, 1643-1647. (Pubitemid 29510566)
22. Marty, G., Tsapis, N., 2008. Monitoring the buckling threshold of drying colloidal droplets using water-ethanol mixtures. Eur. Phys. J. E 27, 213-219.
23. Mitchison, D.A., 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225. (Pubitemid 16150082)
24. Mutschler, E., Derendorf, H., 1995. Drug actions: basic principles and therapeutic aspects. In: Medpharm. CRC press, Stuttgart; Boca Raton (FL); Ann Arbor; London (etc.).
25. Muttil, P., Wang, C., Hickey, A., 2009. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 26, 2401-2416.
26. Najafabadi, A.R., Gilani, K., Barghi, M., Rafiee-Tehrani, M., 2004. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine. Int. J. Pharm. 285, 97-108. (Pubitemid 39361540)
27. Nangia, A., 2008. Conformational polymorphism in organic crystals. Acc. Chem. Res. 41, 595-604.
28. Nolan, L.M., Tajber, L., McDonald, B.F., Barham, A.S., Corrigan, O.I., Healy, A.M., 2009. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur. J. Pharm. Sci. 37, 593-602.
29. Patterson, P.E., M.E.K., Bailey, W.C., Dunlap, N.E., 1999. Chemotherapy of tuberculosis. In: Schlossberg, D. (Ed.), Tuberculosis and Nontuberculous Mycobacterial Infections. W.B. Saunders Co., PA, pp. 71-82.
30. Rabbani, N.R., Seville, P.C., 2005. The influence of formulation components on the aerosolisation properties of spray-dried powders. J. Controlled Release 110, 130-140. (Pubitemid 41713937)
31. Raghavan, S.L., Trividic, A., Davis, A.F., Hadgraft, J., 2001. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 212, 213-221. (Pubitemid 32119447)
32. Rudt, S., Müller, R.H., 1992. In vitro phagocytosis assay of nano- and micro-particles by chemiluminescence. I. Effect of analytical parameters, particle size and particle concentration. J. Controlled Release 22, 263-271.
33. Sacks, L.V., Pendle, S., Orlovic, D., Andre, M., Popara, M., Moore, G., Thonell, L., Hurwitz, S., 2001. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin. Infect. Dis. 32, 44-49. (Pubitemid 32150949)
34. Seville, P.C., Learoyd, T.P., Li, H.Y., Williamson, I.J., Birchall, J.C., 2007. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 178, 40-50. (Pubitemid 47247802)
35. Surendrakumar, K., Martyn, G.P., Hodgers, E.C., Jansen, M., Blair, J.A., 2003. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Controlled Release 91, 385-394.
36. Tajber, L., Corrigan, O.I., Healy, A.M., 2005. Physicochemical evaluation of PVP-thiazide diuretic interactions in co-spray-dried composites - analysis of glass transition composition relationships. Eur. J. Pharm. Sci. 24, 553-563. (Pubitemid 40387269)
37. Takaki, Y., Sasada, Y., Watanabe, T., 1960. The crystal structure of [alpha]-pyrazinamide. Acta Crystallogr. 13, 693-702.
38. Tamura, C., Kuwano, H., Sasada, Y., 1961. Crystallographic data of carboxylic acids and carboxyamides of picoline and pyrazine derivatives. Acta Crystallogr. 14, 693.
39. Thaker, H., Elston, J., 2008. Co-infection with human immunodeficiency virus and tuberculosis.
40. Tsapis, N., Bennett, D., Jackson, B., Weitz, D.A., Edwards, D.A., 2002. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U.S.A. 99, 12001-12005.
41. Tsapis, N., Bennett, D., O'Driscoll, K., Shea, K., Lipp, M.M., Fu, K., Clarke, R.W., Deaver, D., Yamins, D., Wright, J., Peloquin, C.A., Weitz, D.A., Edwards, D.A., 2003. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb) 83, 379-385.
42. Tsapis, N., Dufresne, E.R., Sinha, S.S., Riera, C.S., Hutchinson, J.W., Mahadevan, L., Weitz, D.A., 2005. Onset of buckling in drying droplets of colloidal suspensions. Phys. Rev. Lett. 94, 018302.
43. Vanbever, R., Ben-Jebria, A., Mintzes, J.D., Langer, R., Edwards, D.A., 1999a. Sustained release of insulin from insoluble inhaled particles. Drug Dev. Res. 48, 178-185. (Pubitemid 30115301)
44. Vanbever, R., Mintzes, J.D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R., Edwards, D.A., 1999b. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 16, 1735-1742. (Pubitemid 29530407)
45. Vehring, R., 2008. Pharmaceutical particle engineering via spray drying. Pharm. Res. 25, 999-1022.
46. Wood, G.C., Swanson, J.M., 2007. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 67, 903-914. (Pubitemid 46607390)
47. Zhang, Y., Mitchison, D., 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7, 6-21. (Pubitemid 36427026)
48. Zhang, Y., Permar, S., Sun, Z., 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51, 42-49.
49. Zhang, Y., Wade, M.M., Scorpio, A., Zhang, H., Sun, Z., 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52, 790-795. (Pubitemid 37407806)